Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Elicio Therapeutics, Inc. (ANGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/11/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
SC 13G/A
| Vifor Ltd reports a 0% stake in Elicio Therapeutics, Inc. |
| 06/12/2023 |
3
| Chudnovsky Yekaterina (Director) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/12/2023 |
3
| Haqq Christopher (See Remarks) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/12/2023 |
SC 13D
| Clal Biotechnology Industries Ltd. reports a 7.1% stake in Elicio Therapeutics, Inc. |
| 06/07/2023 |
3
| DeMuth Peter (Chief Scientific Officer) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/07/2023 |
3
| Segal Assaf (Director) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/07/2023 |
3
| RUFFOLO ROBERT R (Director) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/07/2023 |
3
| Matthies Annette (Chief Business Officer) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/07/2023 |
3
| ADAMS JULIAN (Director) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/07/2023 |
3
| Connelly Robert (CEO, President and Director) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/07/2023 |
3
| Ashe Carol Gail (Director) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/05/2023 |
4
| Piekos Brian (CFO) has filed a Form 4 on Elicio Therapeutics, Inc.|
Txns:
| Granted 75,484 options to buy
@ $10, valued at
$754.8k
|
|
| 06/05/2023 |
3
| Piekos Brian (CFO) has filed a Form 3 on Elicio Therapeutics, Inc. |
| 06/02/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Changes in Registra...|
Docs:
|
"Certificate of Merger",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Angion Biomedica Corp. to implement the Reverse Stock Split",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Angion Biomedica Corp. to implement Officer Exculpation",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Angion Biomedica Corp. to implement the name change",
"Suite 501 Boston, MA 02210",
"Form of Indemnification Agreement between the Company and each of its directions and officers",
"Information Rights Letter, by and between Clal Biotechnology Industries Ltd. and Elicio Therapeutics, Inc",
"Letter from Moss Adams LLP",
"NEWTON, Massachusetts, June 1, 2023 ––",
"Elicio Therapeutics Announces Completion of Merger with Angion Biomedica" |
|
| 05/30/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/30/2023 |
8-K
| Other Events Interactive Data |
| 05/23/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/23/2023 |
8-K
| Other Events Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/01/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/21/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 04/13/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 03/29/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 03/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| EISA-ABC LLC reports a 5.7% stake in Angion Biomedica Corp. |
| 02/13/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|
|
|